首页 / 产品 / 蛋白 / 信号通路蛋白

Recombinant Human DOK5 protein

  • 中文名: 对接蛋白5(DOK5)重组蛋白
  • 别    名: DOK5;C20orf180;Docking protein 5
货号: PA2000-1967
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点DOK5
Uniprot No Q9P104
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间 1-198aa
氨基酸序列MECVGTRINDISLGEPDLLATGVEREQSERFNVYLMPSPNLDVHGECALQITYEYICLWDVQNPRVKLISWPLSALRRYGRDTTWFTFEAGRMCETGEGLFIFQTRDGEAIYQKVHSAALAIAEQHERLLQSVKNSMLQMKMSERAASLSTMVPLPRSAYWQHITRQHSTGQLYRLQDVSSPLKLHRTETFPAYRSEH
预测分子量 38.8 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于DOK5重组蛋白的示例参考文献(注:以下文献为虚构示例,实际引用时请查询真实数据库):

---

1. **标题**:*Recombinant DOK5 Protein Enhances Insulin Signaling in Skeletal Muscle Cells*

**作者**:Chen Y, et al.

**摘要**:研究通过哺乳动物细胞系统表达重组DOK5蛋白,发现其能够与胰岛素受体底物(IRS)结合,显著促进骨骼肌细胞的胰岛素信号通路活性,为糖尿病治疗提供潜在分子靶点。

2. **标题**:*Expression and Functional Analysis of DOK5 Recombinant Protein in Neuronal Development*

**作者**:Müller R, et al.

**摘要**:利用大肠杆菌表达并纯化重组DOK5蛋白,证实其通过调控TrkB受体下游的MAPK/ERK通路,促进神经元突触生长和分化,提示其在神经退行性疾病中的潜在应用。

3. **标题**:*DOK5 Recombinant Protein Binds to RET Oncogene and Modulates Cancer Proliferation*

**作者**:Sato H, et al.

**摘要**:研究发现重组DOK5蛋白可与RET酪氨酸激酶结合,抑制甲状腺癌细胞中异常激活的RET信号,为靶向抗癌药物开发提供实验依据。

---

**建议**:如需真实文献,可通过PubMed、Web of Science或Google Scholar检索关键词“DOK5 recombinant protein”“DOK5 signaling”等,并筛选近年的研究论文或权威期刊文章。

背景信息

**Background of DOK5 Recombinant Protein**

The DOK5 (Docking protein 5) recombinant protein is a biologically engineered molecule derived from the *DOK5* gene, which belongs to the DOK family of adaptor proteins. These proteins play critical roles in intracellular signaling by acting as scaffolds to mediate interactions between receptors, kinases, and downstream effectors. DOK5 is primarily expressed in insulin-sensitive tissues, such as skeletal muscle, adipose tissue, and the pancreas, and is notably involved in insulin signaling pathways.

Structurally, DOK5 contains a pleckstrin homology (PH) domain at its N-terminus, which facilitates membrane localization, and a phosphotyrosine-binding (PTB) domain that interacts with phosphorylated tyrosine residues on activated receptors, such as the insulin receptor (IR) or receptor tyrosine kinases (RTKs). The C-terminal region includes multiple tyrosine phosphorylation sites that recruit signaling molecules like Grb2 or SOS, linking extracellular signals to intracellular cascades, including the MAPK/ERK and PI3K/Akt pathways.

Research highlights DOK5's role in modulating insulin sensitivity and glucose homeostasis. It enhances insulin receptor signaling by stabilizing interactions between IR and downstream effectors, making it a potential target for metabolic disorders like type 2 diabetes. Conversely, aberrant DOK5 expression or mutations have been linked to impaired insulin signaling and metabolic dysfunction.

Beyond metabolism, DOK5 is implicated in neuronal development and cancer. In the nervous system, it regulates neurite outgrowth and synaptic plasticity. In oncology, DOK5 may act as a tumor suppressor or promoter depending on context, with studies showing altered expression in cancers like lung adenocarcinoma or neuroblastoma.

Recombinant DOK5 protein, produced via bacterial or mammalian expression systems, is widely used to study its structure-function relationships, interaction partners, and therapeutic potential. Its applications span *in vitro* assays, drug screening, and elucidating molecular mechanisms in metabolic and neoplastic diseases. As a research tool, it continues to provide insights into cellular signaling networks and disease pathogenesis.

相关服务

折叠内容

重组蛋白表达纯化服务

在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。

展开

技术平台

艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。

展开

蛋白工艺开发

艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。

展开

客户数据及评论

折叠内容

大包装询价

×